FeesSafety
Pluang+

Urban One reports Q3 2026 net revenue down 5%, operating loss of $126.6M, plans $20M cost cuts for 2027.

Company Fundamentals
10 Nov 2026, 14:00 WIB
PRNewsWire
View Source
Bearish
Urban One reports Q3 2026 net revenue down 5%, operating loss of $126.6M, plans $20M cost cuts for 2027.

Urban One's Q3 2026 net revenue declined 5% to $88 million, with an operating loss of $126.6 million compared to a $2.5 million income in Q3 2025. The company faced weak advertising demand across radio, digital, and cable TV segments, despite gains from political advertising and new station acquisitions. Adjusted EBITDA fell to $12.3 million, and the company expects $40 million adjusted EBITDA for 2026, revising down prior guidance. Urban One plans at least $20 million in annual cost savings in 2027 to address challenging market conditions.

Urban One's Q3 2026 results provide context for readers following media companies. For readers following media stocks, here is Pluang's market snapshot as of Nov 10, 2026 19:13 WIB: out of 57 priced US media stocks, 31 rose and 18 fell. Notable movers include Fiverr International Ltd (FVRR) at USD 8.68 with a 1-day change of +2.36%, Snap Inc (SNAP) at USD 4.94 with a 1-day change of -2.08%, and Millicom International Cellular S.A. (TIGO) at USD 88.37 with a 1-day change of +1.86%.

More News

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...

Market News
Neutral
59 minutes ago
Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...

Market News
Bullish
59 minutes ago
PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...

Company Fundamentals
Bullish
59 minutes ago
Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...

Company Fundamentals
Bullish
59 minutes ago
Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App